ROBINS CHAD M sold $14.9M of ADPT

ROBINS CHAD M (CEO and Chairman) sold 600,000 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.80 ($24.48–$25.57, $14.88M total) across 4 trades over 2026-08-17 to 2026-08-18.

Original reporting
SEC EDGAR · ROBINS CHAD M
Published Aug 20, 2026, 12:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishMed
01

Why it matters

The insider sale provides fresh data on insider sentiment, a key factor for short‑term traders.

02

Market read

First‑report insider sale of $15M by the CEO, modestly bearish for ADPT.

03

What to watch

No 10b5‑1 plan and the CEO retains a large stake, suggesting confidence in long-term outlook.

Relevance 7/10Novelty 7/10Timing: filed 2026-08-19 after market

Background

Adaptive Biotechnologies (ADPT) is a biotech firm focused on immune profiling and diagnostics.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

CEO Chad M. Robins sold 600,000 shares for $14.9M, reducing his stake to 2.18M shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

A $15M sale by the CEO signals possible concerns, but no 10b5‑1 plan and holdings remain sizable.

Market effects

May affect biotech sector sentiment as insider sales are watched closely.

Limited to US biotech investors.

Low global relevance.

Counterpoint

Insider may be diversifying; the sale does not necessarily indicate negative fundamentals.

Key entities

  • Adaptive Biotechnologies Corp

    Issuer of the Form 4 filing.

  • Chad M. Robins

    CEO and Chairman of ADPT.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.